
|Videos|November 27, 2013
The Difference Between Blocking PD-1 and PD-L1 in Melanoma
Author(s)Harriet Kluger, MD
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the difference between blocking PD-1 and PD-L1 in melanoma.
Advertisement
Clinical Pearls
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the difference between blocking PD-1 and PD-L1 in melanoma.
- The complete biology of PD-L1 is not known yet, though there is a theory that blocking it will be less toxic than blocking PD-1
- The toxicity and activity is different in PD-1 and PD-L1
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap
2
INBRX-106/Pembrolizumab Shows Efficacy in First-Line HNSCC
3
Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC
4
Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment
5







































